Fast Douglas M, Kelley Marian, Viswanathan C T, O'Shaughnessy Jacqueline, King S Peter, Chaudhary Ajai, Weiner Russell, DeStefano Anthony J, Tang Daniel
Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., MS-8118D-2061, Eastern Point Road, Groton, Connecticut 06340, USA.
AAPS J. 2009 Jun;11(2):238-41. doi: 10.1208/s12248-009-9100-9. Epub 2009 Apr 21.
The Conference Report of the 3rd AAPS/FDA Bioanalytical Workshop (Crystal City III) endorsed the concept that assay methods supporting bioanalytical data in submissions must demonstrate assay reproducibility by using incurred samples. The present Workshop was convened to provide a forum for discussion and consensus building about incurred sample assay reproducibility for both nonclinical and clinical studies. Information about current regulatory perspectives on incurred sample reanalysis (ISR) was presented, implications of ISR for both large and small molecules were discussed, and the steering committee put forth recommendations for performing ISR. These recommendations from the Workshop, along with the subsequent evolution of approaches leading to a robust ISR program, may be used by scientists performing bioanalytical assays for regulated studies to provide additional confirmation of assay reproducibility for incurred samples.
第三届美国药学科学家协会/美国食品药品监督管理局生物分析研讨会(水晶城会议三)的会议报告认可了这样一个概念,即支持提交材料中生物分析数据的分析方法必须通过使用实际检测样本证明分析的可重复性。本次研讨会的召开是为非临床和临床研究中实际检测样本分析的可重复性提供一个讨论和达成共识的平台。会上介绍了当前监管机构对实际检测样本重新分析(ISR)的观点,讨论了ISR对大分子和小分子的影响,指导委员会提出了进行ISR的建议。研讨会的这些建议,以及随后为建立一个稳健的ISR计划而不断演变的方法,可被从事受监管研究的生物分析检测的科学家们用来为实际检测样本的分析可重复性提供额外的确认。